NASDAQ · Health care

BioLineRx Ltd. (BLRX)

BioLineRx Ltd. reported revenue of $1.2M in fiscal 2025, down 95.9% from a year earlier. It posted a net loss of $2M. In fiscal 2025 capital spending exceeded operating cash flow by $8.1M. At December 31, 2025 it held $3.3M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on March 27, 2026.

Price

$2.60

+3.18% on the day · September 25, 2026

52-week range $2.15 to $4.56

Market cap

$11.3M

Revenue (FY2025)

$1.2M

-95.9% year on year

Net margin

-171.7%

What BioLineRx Ltd. does

BioLineRx Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BLRX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$1.2M	-$10.3M	-$2M	$0.00	-$8.1M
2024	$28.9M	-$20.4M	-$9.2M	-$0.01	-$43.9M
2023	$4.8M	-$49.7M	-$60.6M	-$0.06	-$22.7M
2022	$0	-$29.2M	-$25M	-$0.03	-$26.4M
2021	$0	-$24.8M	-$27.1M	-$0.04	-$23.7M
2020	n/a	-$22.9M	-$30M	-$0.12	-$23.2M

Where BLRX ranks in Health care

Revenue$1.2M

#564 of 646 in Health care · Bottom 13%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What BioLineRx Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 25, 2026
IPO registration (foreign issuer) F-1
September 24, 2026
Foreign issuer update 6-K
September 10, 2026
Foreign issuer update 6-K
August 31, 2026
Securities offering prospectus 424B5
August 31, 2026
Foreign issuer update 6-K
August 31, 2026
Foreign issuer update 6-K
August 28, 2026
Foreign issuer update 6-K
August 18, 2026
Foreign issuer update 6-K
July 8, 2026
Foreign issuer update 6-K
May 27, 2026
Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 10, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about BLRX

What does BioLineRx Ltd. do?

BioLineRx Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BLRX.

Is BioLineRx Ltd. profitable?

No. In fiscal 2025 it reported a net loss of $2M on revenue of $1.2M.

How much revenue does BioLineRx Ltd. make?

In fiscal 2025 BioLineRx Ltd. reported revenue of $1.2M. That is 95.9% less than a year earlier.

When did BioLineRx Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on March 27, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the iPO registration (foreign issuer) from September 25, 2026.

Similar companies

Compare BLRX with

Compare BLRX with any company

Follow BLRX

Get an email when BioLineRx Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BLRX: get an email when it files

Where the numbers come from

Financial figures are the values BioLineRx Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.